Your browser doesn't support javascript.
loading
10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV) induces memory B cell responses in healthy Kenyan toddlers.
Muema, D M; Nduati, E W; Uyoga, M; Bashraheil, M; Scott, J A G; Hammitt, L L; Urban, B C.
Affiliation
  • Muema DM; Pathogen, Vector and Host Biology Department, KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine-Coast, Kilifi, Kenya.
  • Nduati EW; Pathogen, Vector and Host Biology Department, KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine-Coast, Kilifi, Kenya.
  • Uyoga M; Pathogen, Vector and Host Biology Department, KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine-Coast, Kilifi, Kenya.
  • Bashraheil M; Epidemiology and Demography Cluster, KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine-Coast, Kilifi, Kenya.
  • Scott JA; Epidemiology and Demography Cluster, KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine-Coast, Kilifi, Kenya.
  • Hammitt LL; Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
  • Urban BC; Epidemiology and Demography Cluster, KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine-Coast, Kilifi, Kenya.
Clin Exp Immunol ; 181(2): 297-305, 2015 Aug.
Article in En | MEDLINE | ID: mdl-25845628
ABSTRACT
Memory B cells are long-lived and could contribute to persistence of humoral immunity by maintaining the plasma-cell pool or making recall responses upon re-exposure to an antigen. We determined the ability of a pneumococcal conjugate vaccine to induce anti-pneumococcal memory B cells. Frequencies of memory B cells against pneumococcal capsular polysaccharides from serotypes 1, 6B, 14, 19F and 23F were determined by cultured B cell enzyme-linked immunospot (ELISPOT) in 35 children aged 12-23 months who received pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV). The relationships between plasma antibodies and memory B cell frequencies were also assessed. After two doses of PHiD-CV, the proportion of subjects with detectable memory B cells against pneumococcal capsular polysaccharides increased significantly for serotypes 1 (3-45%; P < 0·01), 19F (21-66%; P < 0·01) and 23F (13-36%; P = 0·02), but not serotypes 6B (24-42%; P = 0·24) and 14 (21-40%; P = 0·06). Correlations between antibodies and memory B cells were weak. Carriage of serotype 19F at enrolment was associated with poor memory B cell responses against this serotype at subsequent time-points (day 30 non-carriers, 82% versus carriers, 0%, P < 0·01; day 210 non-carriers, 72% versus carriers, 33%, P = 0·07). PHiD-CV is capable of inducing memory B cells against some of the component pneumococcal capsular polysaccharides.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bacterial Proteins / Immunoglobulin D / B-Lymphocytes / Carrier Proteins / Vaccination / Haemophilus Vaccines / Haemophilus Infections / Immunologic Memory / Lipoproteins Limits: Female / Humans / Infant / Male Country/Region as subject: Africa Language: En Journal: Clin Exp Immunol Year: 2015 Document type: Article Affiliation country: Kenya

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bacterial Proteins / Immunoglobulin D / B-Lymphocytes / Carrier Proteins / Vaccination / Haemophilus Vaccines / Haemophilus Infections / Immunologic Memory / Lipoproteins Limits: Female / Humans / Infant / Male Country/Region as subject: Africa Language: En Journal: Clin Exp Immunol Year: 2015 Document type: Article Affiliation country: Kenya